These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33330081)

  • 1. NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma.
    Wang Y; Long P; Wang Y; Ma W
    Front Oncol; 2020; 10():593578. PubMed ID: 33330081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
    Jiang T; Wang G; Liu Y; Feng L; Wang M; Liu J; Chen Y; Ouyang L
    Acta Pharm Sin B; 2021 Feb; 11(2):355-372. PubMed ID: 33643817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.
    Zhou KI; Vashistha V; Guo A; Ahmed S; Kelley MJ
    JCO Precis Oncol; 2023 Mar; 7():e2200692. PubMed ID: 36926986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance.
    Liu F; Wei Y; Zhang H; Jiang J; Zhang P; Chu Q
    Front Oncol; 2022; 12():864666. PubMed ID: 35372074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
    Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
    Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel targeted therapeutic option in oncology: tropomyosin receptor tyrosine kinase inhibitors].
    Kiss E; Pápai Z
    Orv Hetil; 2021 Aug; 162(34):1362-1369. PubMed ID: 34428172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
    Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GISTs with
    Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting.
    Bazhenova L; Lokker A; Snider J; Castellanos E; Fisher V; Fellous M; Nanda S; Zong J; Keating K; Jiao X
    Target Oncol; 2021 May; 16(3):389-399. PubMed ID: 33893941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis.
    Lassen U; Bokemeyer C; Garcia-Foncillas J; Italiano A; Vassal G; Paracha N; Marian M; Chen Y; Linsell L; Abrams K
    JCO Precis Oncol; 2023 Jun; 7():e2200651. PubMed ID: 37384865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
    Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors.
    Lang SS; Kumar NK; Madsen P; Gajjar AA; Gajjar E; Resnick AC; Storm PB
    Cancer Genet; 2022 Apr; 262-263():64-70. PubMed ID: 35108662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How selecting best therapy for metastatic
    Ekman S
    Transl Lung Cancer Res; 2020 Dec; 9(6):2535-2544. PubMed ID: 33489816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.